1. Home
  2. ZYME vs VSAT Comparison

ZYME vs VSAT Comparison

Compare ZYME & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • VSAT
  • Stock Information
  • Founded
  • ZYME 2003
  • VSAT 1986
  • Country
  • ZYME United States
  • VSAT United States
  • Employees
  • ZYME 290
  • VSAT N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • VSAT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • ZYME Health Care
  • VSAT Technology
  • Exchange
  • ZYME Nasdaq
  • VSAT Nasdaq
  • Market Cap
  • ZYME 956.0M
  • VSAT 1.1B
  • IPO Year
  • ZYME 2017
  • VSAT 1996
  • Fundamental
  • Price
  • ZYME $13.88
  • VSAT $8.89
  • Analyst Decision
  • ZYME Buy
  • VSAT Buy
  • Analyst Count
  • ZYME 6
  • VSAT 7
  • Target Price
  • ZYME $19.17
  • VSAT $19.00
  • AVG Volume (30 Days)
  • ZYME 565.8K
  • VSAT 3.4M
  • Earning Date
  • ZYME 03-05-2025
  • VSAT 02-04-2025
  • Dividend Yield
  • ZYME N/A
  • VSAT N/A
  • EPS Growth
  • ZYME N/A
  • VSAT N/A
  • EPS
  • ZYME N/A
  • VSAT N/A
  • Revenue
  • ZYME $62,199,000.00
  • VSAT $4,527,274,000.00
  • Revenue This Year
  • ZYME $21.53
  • VSAT $7.71
  • Revenue Next Year
  • ZYME N/A
  • VSAT $1.73
  • P/E Ratio
  • ZYME N/A
  • VSAT N/A
  • Revenue Growth
  • ZYME N/A
  • VSAT 36.25
  • 52 Week Low
  • ZYME $7.97
  • VSAT $6.69
  • 52 Week High
  • ZYME $17.70
  • VSAT $26.70
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 48.04
  • VSAT 50.35
  • Support Level
  • ZYME $12.80
  • VSAT $7.45
  • Resistance Level
  • ZYME $14.63
  • VSAT $10.65
  • Average True Range (ATR)
  • ZYME 0.85
  • VSAT 0.75
  • MACD
  • ZYME -0.04
  • VSAT -0.05
  • Stochastic Oscillator
  • ZYME 25.29
  • VSAT 45.00

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About VSAT ViaSat Inc.

Viasat Inc provides bandwidth technologies and services in three segments: satellite services: which provides satellite-based high-speed broadband services to consumers, enterprises, and commercial airlines; commercial networks: which develops end-to-end communication and connectivity systems; and government systems: which produces network-centric Internet Protocol-based secure government communication systems. A large majority of the firm's revenue is generated in the United States, it also has its presence in non U.S. countries.

Share on Social Networks: